Next Phase Newsletter

A venture capital firm acts as a drug discovery copilot and seed investor. The firm has a unique copiloting model where they can help founders stay incredibly lean while generating the preclinical data package necessary for a high-quality Series A. The firm invests in therapeutics companies at the Seed stage and what may sometimes look like a Series A round with typical check sizes ranging from $5-10M USD. The firm can be first or second money in and is geography-agnostic. 
 
The firm solely invests in therapeutics and is modality- and indication-agnostic. Companies can be single asset or platform focused. The firm can fund anything from a well-defined “idea on paper” to existing companies with significant proof of concept data. 
 
The firm does not have specific management team requirements. The firm acts as a lead investor and typically does not take a controlling position but requests a right to take a board seat if applicable. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm with offices in Canada is primarily interested in investing in companies in the digital health sector but will also consider medical and diagnostic devices that have a significant digital component to them. Esplanade is looking to participate in the Seed to Series B financings of early-stage companies with typical investments between USD $0.5M-2.5M. The firm is currently operating out of its second fund in which it has made five investments after making thirteen investments out of its inaugural fund. Esplanade participates in equity investments including SAFEs and convertible notes. The firm invests primarily in companies based in Canada, the United States, Europe, and Israel. 
 
The firm is primarily interested in investing in companies in the digital health sector but will also consider medical and diagnostic devices that have a significant digital component to them. The firm is open to all modalities within digital health but requires that the technologies be patient facing or have a patient component. The firm will not consider investments in biotech or pharma but will consider digital therapeutics. The firm is phase agnostic and will invest in developing as well as on the market technologies. The firm will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm is disease agnostic and will consider companies across all indications but prefers that there is ample market size for the technology. 
 
The firm prefers to work with experienced management teams. The firm looks to invest in companies in which the founder has a significant stake in the business. The firm is an active and strategic investor and will take a board seat or board observer role as determined by check size on a case-by-case basis. The firm will participate both as lead and co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Based in the US, a venture capital firm invests in early-stage life sciences and healthcare. The firm seeks early-stage investment opportunities from seed to series A, generally investing $50k to $1.5M in the initial round, with potential for follow-on investments up to $3M. The firm is focused regionally based companies (those close to their office) but also seek opportunities globally. The firm is open to both leading and co-investing. 
 
The firm invests in medical devices, diagnostics and digital health. The firm is open to considering all subsectors and indications. 
 
While the firm can invest in companies based elsewhere under certain circumstances, the firm is primarily focused on companies in the same state. The firm is active in supporting their portfolio companies and will consider taking a board seat on a case-by-case basis. Additionally, the firm is open to engages with entrepreneurs and founders at a very early stage. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A globally diversified healthcare venture capital firm headquartered in Singapore. The firm’s mission is to deliver medical solutions and savings to over 100M people around the world. The firm seeks out visionary entrepreneurs who combine integrity, intelligence, and passion to address pressing healthcare challenges innovatively and ethically. The firm’s globally diversified portfolio comprises 60% allocation in the U.S. and the remaining 40% distributed across Singapore, India, and the EU.  

The firm’s engagement extends beyond financial investment. The firm provides robust post-investment support, focusing on strategy development, distribution, cross-border expansion, and manufacturing/OEM partnerships. They strive to establish an ecosystem that fosters collaboration among start-ups, government bodies, clinical, investment, and commercial partners. This approach ensures that portfolio companies receive comprehensive support, aiding in their growth and impactful contribution to the healthcare sector. 
 
Focused on early to growth-stage investments, the firm specializes in sectors including medical devices, digital health, healthcare services, and AI-empowered solutions. The firm has particular interests in critical areas such as oncology, ophthalmology, brain health, orthopedics, cardiology, and other chronic diseases management. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment firm based in Australia is backed by one of Australia’s largest family offices. With its current fund, the firm will focus exclusively on life sciences & healthcare. The firm is focused on investing early-stage companies – while the firm has a focus on supporting the Australian ecosystem, the firm is open to global opportunities. 
 
The firm seeks to invest in therapeutics, diagnostics, and digital health companies and has no particular preference on specific types of technologies or disease area/indication. The firm prefers to see strong pre-clinical data, and is open to both pre-clinical and clinical projects. The firm does not invest in medical device companies at this time. 
 
The firm seeks to support companies with innovative technology, and is open to working with both first-time and experienced management teams. The firm can act as either lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment group located in the U.S. and Europe invests in early-stage life science companies from Seed to Series C. Typical check size can be up to $60M USD and varies depending on the fit. The firm makes investments to global companies acting as both a lead and co-investor. 
 
The firm is seeking to invest in biotech therapeutics, diagnostics, and medical devices. The firm is indication- and sub sector-agnostic and can fund companies from Phase I to Phase IV. 
 
The firm does not require to take a board seat, but rather seeks to run the clinical trial programs in exchange. The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A family office based in the US makes seed-stage and venture-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million. The firm is open to opportunities worldwide, and currently has portfolio companies in North America, Europe and Oceania. 
 
The firm funds early-stage companies across neurodegeneration, psychiatry and neurotech and also funds platform opportunities that raise the tide towards precision neuro. The firm invests across modalities. 
 
The firm invests in privately held companies and backs top scientists, who are pursuing breakthrough approaches rather than traditional. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.